Aptose Biosciences Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Product Pipeline
    • Overview
    • Tuspetinib for AML
    • Luxeptinib for B-cell Tumors
    • Luxeptinib for Myeloid Tumors
    • Posters & Presentations
  • Clinical Trials
    • Overview
    • Luxeptinib for CLL & NHL
    • Luxeptinib for AML
    • Tuspetinib for AML
    • Expanded Access
  • News
    • Press Releases
    • Presentations
    • Events
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • SEDAR
    • Governance
  • Join Us
    • Values & Culture
    • Perks & Benefits
    • Explore Careers
  • Contact

Press Releases

News

News

  • Press Releases
  • Presentations
  • Events

Aptose Announces Dosing of First Patient with 120 mg of Tuspetinib in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy after Dose Escalation Decision by Safety Review Committee

May 20, 2025 7:30am EDT

Aptose Selected for Prestigious Oral Presentation of Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2025 EHA Congress

May 14, 2025 1:07pm EDT

Aptose Reports First Quarter 2025 Results

May 08, 2025 7:00am EDT

Aptose Provides Clinical Update for the Tuspetinib-based Triple Drug Frontline Therapy in Newly Diagnosed AML Patients from the Phase 1/2 TUSCANY Trial

May 05, 2025 7:00am EDT

Aptose Announces Auditor Not Standing for Re-Appointment

Apr 23, 2025 5:00pm EDT

Aptose to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference

Apr 23, 2025 7:30am EDT

Aptose Common Shares to Delist from Nasdaq as of April 2, 2025

Apr 01, 2025 8:30am EDT

Aptose Reports Year End 2024 Results and Corporate Highlights

Mar 28, 2025 8:01am EDT

Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance

Mar 17, 2025 7:30am EDT

Aptose Announces Positive Clinical Safety Review Committee (CSRC) Approval to Dose Escalate in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy with Tuspetinib Amid Complete Responses and Favorable Safety in First Cohort

Feb 20, 2025 7:32am EST
RSS
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...32
Next
© 2025 Aptose Biosciences Inc. All Rights Reserved.
Privacy Policy Clinical Trials Policy Disclaimer Sitemap Manage Cookie Preferences